Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics Inc (BNGO) delivers cutting-edge optical genome mapping solutions for advanced genomic research. This news hub provides investors and researchers with essential updates on the company's innovations in structural variation analysis.
Access official press releases, financial disclosures, and technology developments in one centralized location. Track updates spanning product launches, clinical study collaborations, and peer-reviewed research validations of Bionano's OGM platform. Our curated collection ensures timely access to material developments impacting the genome analysis sector.
Key focus areas include regulatory milestones, partnership announcements, and scientific advancements demonstrating Bionano's leadership in next-generation cytogenetics. All content maintains strict factual accuracy required for informed investment decisions and research applications.
Bookmark this page for streamlined monitoring of Bionano's progress in transforming genomic medicine through high-resolution genome analysis tools. Verify critical updates directly from primary sources with our comprehensive news aggregation.
Bionano Genomics, Inc. (Nasdaq: BNGO) announced significant upgrades to its suite of computational tools for comprehensive cancer analysis. The enhancements to the VIA™ software solution improve the detection and interpretation of aneusomies, small structural variants, and copy number variants. The upgrades also include dynamic visualization tools for better representation of findings, automated analysis, and interpretation of variants, and standardized Phred scale calculation for SV confidence scores.
Bionano Genomics, Inc. (BNGO) reported Q1 2024 revenue of $8.8 million, an 18% increase over Q1 2023. The company's total installed base of optical genome mapping systems grew by 34%, with 8,249 nanochannel array flowcells sold, a 58% increase. BNGO announced a partnership with Hangzhou Diagens Biotechnology, a direct offering of $10 million, and planned software enhancements for cancer analysis. The company reiterated full-year revenue guidance of $37.0 to $41.0 million for 2024.
Bionano Genomics, Inc. (Nasdaq: BNGO) will report its first quarter 2024 financial results on May 8, 2024, with a conference call and webcast to discuss recent corporate progress. Participants can join the event via phone or webcast and access a replay on the company's investor relations website.
Bionano Genomics, Inc. will present at the RBC Capital Markets 2024 Global Healthcare Conference, with Erik Holmlin, PhD, as the presenter. The conference will take place on May 15, 2024, and a replay will be available on the Bionano website.
FAQ
What is the current stock price of Bionano Genomics (BNGO)?
What is the market cap of Bionano Genomics (BNGO)?
